This clinical trial focuses on patients with cMET-dependent cancers, which are a type of cancer that relies on a specific protein called cMET for growth. The study involves the use of a medication called capmatinib, also known by its code name INC280. Capmatinib is taken as a film-coated tablet and is designed to target and inhibit the activity of the cMET protein, potentially slowing down or stopping the growth of these cancers. In addition to capmatinib, the study also involves another medication called nazartinib, known by its code name EGF816, which is taken as a hard capsule. Another medication, gefitinib, is also part of the study and is taken as a film-coated tablet.

The purpose of this study is to evaluate the long-term safety of capmatinib when used alone or in combination with other treatments. Participants in this study have previously been treated with capmatinib in a Novartis-sponsored trial and are continuing their treatment in this study. The study will monitor the occurrence of any adverse events (AEs) or serious adverse events (SAEs) to ensure the safety of the treatment over an extended period.

Participants will continue their treatment with capmatinib, either alone or in combination with other medications, for a maximum period of 120 weeks. The study will involve regular visits to monitor the participants’ health and any side effects they may experience. The goal is to ensure that the treatment remains safe and effective for those who are benefiting from it. This study is expected to continue until July 2027.